Table 1.
Summary of tenascin immunostaining of normal liver, non-tumoral gallbladder, and hepatobiliary cancers.
| Tissue | Anti-TNC | Anti-TNW* | ||||||
|---|---|---|---|---|---|---|---|---|
| - | + | ++ | +++ | - | + | ++ | +++ | |
| Liver (n = 13)** | 0/13 | 5/13 | 7/13 | 1/13 | 13/13 | 0/13 | 0/13 | 0/13 |
| Gallbladder (n = 6)† | 0/6 | 1/6 | 2/6 | 3/6 | 5/6 | 1/6¶ | 0/6 | 0/6 |
| ICC (n = 8)‡ | 0/8 | 0/8 | 0/8 | 8/8 | 0/8 | 1/8 | 2/8 | 5/8 |
| CPHBD (n = 7)§ | 0/7 | 0/7 | 1/7 | 6/7 | 0/7 | 2/7 | 2/7 | 3/7 |
| CGB (n = 11)‖ | 0/11 | 0/11 | 0/11 | 11/11 | 0/11 | 1/11 | 3/11 | 7/11 |
| CGB liver metastasis (n = 4) | 0/4 | 0/4 | 0/4 | 4/4 | 0/4 | 0/4 | 2/4 | 2/4 |
*Intensity of anti-tenascin-C (TNC) and anti-tenascin-W (TNW) immunostaining: -, absent; +, weak; ++, moderate; +++, high.
**Histologically normal liver, negative for HIV, hepatitis B, and hepatitis C.
†From cholecystectomy due to cholecystitis.
‡Intrahepatic cholangiocarcinoma.
§Carcinoma of perihilar bile ducts.
‖Carcinoma of the gallbladder.
¶Focal positivity.